Dr. Koontz gives an overview of ASTRO discussion on new RTOG-0815 data

SAP Partner | <b>GenesisCare</b>

“I would say what RTOG-0815 has provided is data to have an intelligent conversation with our patients and provide them numbers so that they know what to expect,” says Bridget F. Koontz, MD.

In this video, Bridget F. Koontz, MD, provides an expert opinion on the methods and findings of the study, “Dose escalated radiotherapy alone or in combination with short-term androgen suppression for intermediate risk prostate cancer: outcomes from the NRG Oncology/RTOG 0815 randomized trial,” presented recently at the 2021 American Society for Radiation Oncology Annual Meeting. Koontz is a radiation oncologist, US chief medical officer, and deputy global chief medical officer for GenesisCare.